Reprogrammed immune cells take aim at deadly brain cancer

This early-stage study tested the safety of a personalized cell therapy called tisagenlecleucel in patients with primary central nervous system lymphoma, a rare and aggressive cancer of the brain. The therapy involves collecting a patient's own immune cells, modifying them in a lab to better target cancer, and then infusing them back. The main goal was to see if this approach was safe and tolerable for these patients, while also checking for early signs that it might help control the disease.